| Symbol | ANL |
|---|---|
| Name | ADLAI NORTYE LTD. |
| Sector | HEALTH CARE |
| Region | Caribbean |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | UGLAND HOUSE,PO BOX 309, GRAND CAYMAN, Cayman Islands |
| Telephone | 848 230 7430 |
| Fax | — |
| — | |
| Website | https://www.adlainortye.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001944552 |
| Description | Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The Companys pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025. Additional info from NASDAQ: |
NASDAQ traded attribute type Security_Name was changed. Previous value: Adlai Nortye Ltd. - American Depositary Shares. New value: Adlai Nortye Group Ltd. - American Depositary Shares.
Read moreANL attributes changed: Attr: Sec_name Adlai Nortye Ltd. - American Depositary Shares -> Adlai Nortye Group Ltd. - American Depositary Shares;
Read moreNASDAQ symbol attribute type Security_Name was changed. Previous value: Adlai Nortye Ltd. - American Depositary Shares. New value: Adlai Nortye Group Ltd. - American Depositary Shares.
Read moreNew Form SCHEDULE 13G/A - Adlai Nortye Ltd. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001231919-26-000929 <b>Size:</b> 18 KB
Read moreNew Form SCHEDULE 13G/A - Adlai Nortye Ltd. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003685 <b>Size:</b> 10 KB
Read moreAdlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
Read moreAdlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
Read moreAdlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
Read moreNew Form 3 - Adlai Nortye Ltd. <b>Filed:</b> 2026-07-15 <b>AccNo:</b> 0001683168-26-005542 <b>Size:</b> 6 KB
Read moreDirector Ji Ping 🟢 acquired 136.7K shares of Adlai Nortye Ltd. (ANL) Transaction Date: Dec 16, 2018 | Filing ID: 000003
Read more